RESUMEN
The 28-day repeat-dose oral and genetic toxicity of eicosapentaenoic acid triglyceride oil (EPA oil) produced from genetically modified Yarrowia lipolytica yeast were assessed. Groups of rats received 0 (olive oil), 940, 1880, or 2820 mg EPA oil/kg/day, or fish oil (sardine/anchovy source) by oral gavage. Lower total serum cholesterol was seen in all EPA and fish oil groups. Liver weights were increased in the medium and high-dose EPA (male only), and fish oil groups but were considered non-adverse physiologically adaptive responses. Increased thyroid follicular cell hypertrophy was observed in male high-dose EPA and fish oil groups, and was considered to be an adaptive response to high levels of polyunsaturated fatty acids. No adverse test substance-related effects were observed on body weight, nutritional, or other clinical or anatomic pathology parameters. The oil was not mutagenic in the in vitro Ames or mouse lymphoma assay, and was not clastogenic in the in vivo mouse micronucleus test. In conclusion, exposure for 28 days to EPA oil derived from yeast did not produce adverse effects at doses up to 2820 mg/kg/day and was not genotoxic. The safety profile of the EPA oil in these tests was comparable to a commercial fish oil.
Asunto(s)
Ácidos Araquidónicos/toxicidad , Aceites/toxicidad , Triglicéridos/toxicidad , Yarrowia/metabolismo , Administración Oral , Animales , Ácidos Araquidónicos/administración & dosificación , Ácidos Araquidónicos/biosíntesis , Peso Corporal/efectos de los fármacos , Línea Celular Tumoral , Colesterol/sangre , Ingestión de Alimentos/efectos de los fármacos , Femenino , Aceites de Pescado/toxicidad , Hiperplasia , Hígado/efectos de los fármacos , Hígado/patología , Masculino , Ratones , Ratones Endogámicos ICR , Pruebas de Micronúcleos , Pruebas de Mutagenicidad , Aceites/administración & dosificación , Aceites/metabolismo , Aceite de Oliva , Aceites de Plantas/toxicidad , Ratas , Ratas Sprague-Dawley , Medición de Riesgo , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/patología , Factores de Tiempo , Pruebas de Toxicidad , Triglicéridos/administración & dosificación , Triglicéridos/biosíntesis , Yarrowia/genéticaRESUMEN
The safety of eicosapentaenoic acid (EPA) oil produced from genetically modified Yarrowia lipolytica yeast was evaluated following 90 days of exposure. Groups of rats received 0 (olive oil), 98, 488, or 976 mg EPA/kg/day, or GRAS fish oil or deionized water by oral gavage. Rats were evaluated for in-life, neurobehavioral, anatomic and clinical pathology parameters. Lower serum cholesterol (total and non-HDL) was observed in Medium and High EPA and fish oil groups. Lower HDL was observed in High EPA and fish oil males, only at early time points. Liver weights were increased in High EPA and Medium EPA (female only) groups with no associated clinical or microscopic pathology findings. Nasal lesions, attributed to oil in the nasal cavity, were observed in High and Medium EPA and fish oil groups. No other effects were attributed to test oil exposure. Exposure to EPA oil for 90 days produced no effects at 98 mg EPA/kg/day and no adverse effects at doses up to 976 mg EPA/kg/day. The safety profile of EPA oil was comparable to that of GRAS fish oil. These results support the use of EPA oil produced from yeast as a safe source for use in dietary supplements.